ALK and non-small cell lung carcinoma: As a result of pursuing treatment for oligoprogression, a request was made to access to CERITINIB (which was studied in Non-Small Cell Lung Cancer (NSCLC) with ALK rearrangement) through an expanded access program in 2014, but was refused in November (12).